Current Report Filing (8-k)
June 29 2022 - 8:31AM
Edgar (US Regulatory)
0001551152
false
--12-31
Common Stock, $0.01 Par Value
ABBV
0001551152
2022-06-23
2022-06-23
0001551152
us-gaap:CommonStockMember
exch:XNYS
2022-06-23
2022-06-23
0001551152
exch:XCHI
us-gaap:CommonStockMember
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes1.500Percentdue2023Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes1.375Percentdue2024Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes1.250Percentdue2024Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes0.750Percentdue2027Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes2.125Percentdue2028Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes2.625Percentdue2028Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes2.125Percentdue2029Member
exch:XNYS
2022-06-23
2022-06-23
0001551152
abbv:SeniorNotes1.250Percentdue2031Member
exch:XNYS
2022-06-23
2022-06-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): June 23, 2022
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-35565 |
|
32-0375147 |
(State or other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (847) 932-7900
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, $0.01 Par Value |
|
ABBV |
|
New York Stock Exchange Chicago Stock Exchange |
1.500% Senior Notes due 2023 |
|
ABBV23B |
|
New York Stock Exchange |
1.375% Senior Notes due 2024 |
|
ABBV24 |
|
New York Stock Exchange |
1.250% Senior Notes due 2024 |
|
ABBV24B |
|
New York Stock Exchange |
0.750% Senior Notes due 2027 |
|
ABBV27 |
|
New York Stock Exchange |
2.125% Senior Notes due 2028 |
|
ABBV28 |
|
New York Stock Exchange |
2.625% Senior Notes due 2028 |
|
ABBV28B |
|
New York Stock Exchange |
2.125% Senior Notes due 2029 |
|
ABBV29 |
|
New York Stock Exchange |
1.250% Senior Notes due 2031 |
|
ABBV31 |
|
New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Common Stock, $0.01 Par Value |
ABBV |
Item 5.03 Amendments to Articles
of Incorporation or Bylaws; Change in Fiscal Year.
On June 23, 2022, the Board of Directors of
AbbVie Inc. (the “Company”) approved and adopted Amended and Restated By-laws to amend Article IV, Section 4.7 to change the
name of the Public Policy Committee to the Public Policy and Sustainability Committee.
The foregoing description
of the Company’s Amended and Restated By-laws is qualified in its entirety by reference to the full text of the Amended and Restated
By-laws, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
ABBVIE
INC. |
|
|
|
|
Date: |
June
29, 2022 |
By: |
/s/
Laura J. Schumacher |
|
|
|
Laura
J. Schumacher |
|
|
|
Vice
Chairman, External Affairs and Chief Legal Officer |
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024